Butorphanol Tartrate 2mg/ml Injection
Butorphanol 2mg/ml is a synthetic opioid analgesic with mixed agonist-antagonist properties. This Schedule IV controlled substance provides effective pain relief for moderate to severe acute pain while producing less respiratory depression and lower abuse potential compared to full mu-opioid agonists like morphine and fentanyl.
Unique Pharmacological Profile
Butorphanol differs from traditional opioids through its complex receptor interactions:
- Mu-opioid receptor: Partial agonist/antagonist – analgesia with ceiling effect
- Kappa-opioid receptor: Full agonist – contributes to analgesia and sedation
- Sigma receptor: Antagonist activity
- Ceiling effect on respiratory depression: Unlike morphine, respiratory depression plateaus rather than escalating with dose
- Lower abuse liability: Reduced euphoria compared to full agonists
This pharmacological profile makes butorphanol valuable for specific clinical scenarios where traditional opioids present safety concerns.
Clinical Applications and Pain Management
Primary indications:
- Post-operative pain: Balanced anesthesia supplementation and post-surgical analgesia
- Labor pain: Obstetric analgesia with minimal neonatal respiratory depression
- Migraine headache: Nasal spray formulation (injectable for refractory cases)
- Renal colic: Effective for kidney stone pain
- Trauma pain: Emergency department analgesia
Special advantages:
- Obstetric anesthesia – safer for mother and neonate than morphine or meperidine
- Renal failure patients – hepatic metabolism with minimal active metabolites
- Elderly patients – ceiling effect provides safety margin
- Patients with prior opioid use disorder – lower euphoria reduces relapse risk
Comparative Potency and Dosing
| Parameter | Butorphanol | Morphine | Nalbuphine |
|---|---|---|---|
| Relative potency | 5-7x morphine | 1x (baseline) | 0.8-1x morphine |
| Duration | 3-4 hours | 3-4 hours | 3-6 hours |
| Ceiling effect | Yes (respiratory) | No | Yes (respiratory) |
| Schedule | IV | II | IV |
| Euphoria | Moderate | High | Low |
Butorphanol provides analgesic potency comparable to or exceeding morphine with the safety advantages of partial agonism.
Dosage Guidelines and Administration
Intravenous/Intramuscular dosing:
- Initial adult dose: 1-2mg IV or 2mg IM
- Repeat: 1-2mg every 3-4 hours as needed
- Maximum: Limited by ceiling effect rather than absolute maximum
- Elderly: Start at 0.5-1mg due to increased sensitivity
Intravenous infusion:
- 0.01-0.03 mg/kg/hour for continuous post-operative analgesia
- Patient-controlled analgesia (PCA) at 0.2-0.5mg per demand dose
Administration considerations:
- IV injection over 3-5 minutes reduces dizziness and nausea
- Monitor for sedation and respiratory rate
- Have naloxone available for emergency reversal
Obstetric Anesthesia Excellence
Butorphanol holds special significance in obstetric pain management:
- Maternal safety: Minimal respiratory depression compared to morphine
- Fetal/neonatal effects: Lower Apgar depression than meperidine
- Duration appropriate for labor: 3-4 hour analgesia window
- No neonatal naloxone requirement: Unlike full agonists in high doses
Typical labor dosing: 1-2mg IV or IM, may repeat once after 4 hours if delivery not imminent. Transition to regional anesthesia (epidural) if prolonged labor expected.
Safety Profile and Contraindications
Advantages over full agonists:
- Respiratory depression ceiling at higher doses
- Lower addiction potential
- Schedule IV (less restrictive than Schedule II)
- No significant histamine release (unlike morphine)
- Minimal cardiovascular effects
Contraindications and cautions:
- Hypersensitivity to butorphanol
- Patients on full opioid agonists (may precipitate withdrawal)
- Respiratory depression not from opioid pathophysiology
- Severe hepatic impairment (reduced clearance)
Side Effects and Management
Common effects:
-
li>Sedation and dizziness (most frequent – patients should not drive)
- Nausea and vomiting (less than morphine, treatable with antiemetics)
- Confusion and disorientation (especially in elderly)
- Clumsiness and ataxia
- Sweating and flushing
Unique to kappa agonism:
- Dysphoria and hallucinations (uncommon but possible)
- Psychotomimetic effects at high doses
- These limit recreational abuse potential
Critical Drug Interactions
Major interactions:
- Full opioid agonists: Butorphanol may reduce their effects or precipitate withdrawal in dependent patients
- CNS depressants: Additive sedation with alcohol, benzodiazepines (Xanax, Valium), barbiturates
- MAO inhibitors: Potential hypertensive crisis
- Antihistamines: Additive sedation
Precipitated withdrawal risk: Patients physically dependent on morphine, heroin, oxycodone, or fentanyl may experience withdrawal if given butorphanol alone. Use with caution or ensure adequate time since last full agonist dose.
Transition from Full Agonist Opioids
When switching patients from morphine, oxycodone, or hydromorphone to butorphanol:
- Wait for mild withdrawal symptoms before first butorphanol dose
- Start with 1mg to assess tolerance
- Expect 20-30% dose increase needed compared to calculated equianalgesic
- Monitor for withdrawal signs: restlessness, lacrimation, rhinorrhea, yawning
Comparison with Nalbuphine and Pentazocine
Butorphanol is one of three commercially available mixed agonist-antagonist opioids:
-
li>Butorphanol: Intermediate kappa/mu profile, best analgesia, moderate sedation
- Nalbuphine: More kappa-selective, less analgesia, less sedation, useful for opioid-induced pruritus
- Pentazocine: More kappa effects, more dysphoria, less popular in modern practice
Butorphanol generally provides the most reliable analgesia among the three while maintaining safety advantages.
Ordering Butorphanol from Our Pharmacy
We supply pharmaceutical-grade butorphanol 2mg/ml injection for legitimate medical applications:
- Authentic butorphanol tartrate from licensed manufacturers
- Sterile injectable formulation with lot traceability
- Competitive pricing on mixed agonist-antagonist opioids
- Discreet shipping with cold chain options
- 24/7 customer support: +1 951 597 6118 (call, text, WhatsApp)
- Payment methods: Credit cards, Bitcoin (10% discount), CashApp, Venmo, Zelle, Chime
Appropriate medical documentation required for all Schedule IV opioid purchases. Our pharmacy team provides guidance on safe transition protocols from full agonists.
Alternative Mixed Agonist-Antagonist Options
Depending on clinical requirements:
- Nalbuphine – For patients needing less sedation or with opioid-induced pruritus
- Buprenorphine – Longer duration for chronic pain or addiction treatment
- Pentazocine – Alternative kappa-agonist profile
- Tramadol – Weaker mixed mechanism for mild to moderate pain
Contact Information
?? Phone/Text/WhatsApp: +1 951 597 6118
?? Email: sales@opioidspharmacy.com
?? Website: www.opioidspharmacy.com
Licensed pharmacy specializing in anesthesia and pain management medications. DEA-compliant with strict controlled substance handling protocols.
Related pain relief products: Nalbuphine injection, Morphine sulfate, Dilaudid (hydromorphone), Fentanyl citrate for comprehensive acute pain management solutions.
